Newbury Pharmaceuticals AB has published its annual report for the 2024/2025 financial year.
The annual report for 2024/2025 is available to download on the company's website www.newburypharma.com/investors/. The Annual General Meeting will be held on Wednesday, January 14, 2026.
For more information, contact:
Karl Karlsson, CEO
karl.karlsson@newburypharma.com
Mobile: +46 46 12 11 20
www.newburypharma.com
About Newbury Pharmaceuticals
Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and an extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.
Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.
Attachments
Newbury Pharmaceuticals Arsredovisning September 2024 Augusti 2025
© Modular Finance, source Nordic Press Releases